Roclatan netarsudil/latanoprost: Phase III started

Aerie began the double-blind, U.S. Phase III Mercury 2 trial to compare once-daily netarsudil 0.02%/latanoprost

Read the full 158 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE